2025 · 4th Quarter (Oct 1 - Dec 31)

GENENTECH, INC.

Filed by MARSHALL & POPP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 16, 2026
Income: $60,000.00
Expenses: Not reported
Registrant: MARSHALL & POPP, LLC
Client: GENENTECH, INC.
Filing UUID: 9393c4cf-8d41-4273-a603-4c5bf3a7120a
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

Literal federal measure citations: H.R. 1492

CPT · Copyright/Patent/Trademark

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Literal federal measure citations: S.1040, S.1041

TRD · Trade (domestic/foreign)

Issues related to tariff and trade policy.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.